Skip to content
Screener

Accrued Expenses at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$16.56M+59.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$15M+481%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$39.34M+17.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$14.17M+73.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.42M-79.3%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$121.9M+13.8%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands)March 31,2026December 31,2025
Accrued taxes$13,110$10,919
Accrued payroll and benefits4,93811,457
Accrued professional fees4,3475,936
Accrued preclinical and clinical expenses3,8014,667
Other current liabilities3,1763,579
Accrued inventory1,0401,005
Accrued construction in progress7842,189
Accrued expenses and other current liabilities$31,196$39,752

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s accrued expenses?
Krystal Biotech, Inc. (KRYS) reported accrued expenses of $3.18M in Q1 2026.
How has Krystal Biotech, Inc.'s accrued expenses changed year-over-year?
Krystal Biotech, Inc.'s accrued expenses decreased by 6.3% year-over-year, from $3.39M to $3.18M.
What is the long-term trend for Krystal Biotech, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s accrued expenses has grown at a 167.8% compound annual growth rate (CAGR), from $26K to $3.58M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Krystal Biotech, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude